Biotech financing has changed in the past few years. Companies want to know is the current public market real? How long will it be open? Should we confidentially submit under the JOBS act? Should we consider an option deal as an alternative to another private round? Just how does royalty financing work at an early stage company?
Eckard Weber, Domain Associates
Kleanthis G. Xanthopoulos, Ph.D., President & CEO, Regulas Therapeutics, Inc.
Todd Davis, Managing Director, Healthcare Royalty Partners
Thank you Sponsors: